Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer
Neoadjuvant chemotherapy is unlikely to downstage tumors with a low-intermediate RS, higher ER%/PR%, or lower Ki-67%. Breast-conserving surgery after NET was most dependent on ER%. Findings could facilitate treatment decision-making based on tumor biology and racial/socioeconomic disparities and improve patient counseling on the likelihood of successful BCS.
Authors
- Rita Nanda (ORCID: https://orcid.org/0000-0001-5248-0876)
- Dezheng Huo (ORCID: https://orcid.org/0000-0002-4041-1678)
- Frederick M. Howard (ORCID: https://orcid.org/0000-0002-6039-1141)
- Sudha Yarlagadda (ORCID: https://orcid.org/0000-0002-5314-7175)
- Sarah P. Shubeck (ORCID: https://orcid.org/0000-0001-8831-2428)
- Jincong Q. Freeman (ORCID: https://orcid.org/0000-0002-1119-2146)
- Nan Chen (ORCID: https://orcid.org/0000-0001-8536-6631)
Institutions
- Chicago Department of Public Health (US)
- University of Chicago (US)
- Illinois Arts Council Agency (US)
- Cancer Genetics (United States) (US)
Publication Details
- Journal
- Annals of Surgical Oncology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1245/s10434-024-16160-5
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.86
Funders
- U.S. Department of Defense
- Breast Cancer Research Foundation
- Susan G. Komen
- Agency for Healthcare Research and Quality
- National Institute on Aging
- National Cancer Institute